SearchBar Icon

Bronchiectasis Therapeutics Pipeline to Receive More R&D Investments in the Future

Published Date:   November 2017

Bronchiectasis currently exhibits a pipeline with 13 drug candidates, P&S Intelligence

Bronchiectasis Therapeutics Pipeline 2017

The study analysed that the Bronchiectasis therapeutics pipeline comprises approximately 13 drug candidates in different stages of development. Bronchiectasis is a condition in which damage to the airways causes them to widen and become flabby and scarred. The airways are tubes that carry air in and out of lungs. Bronchiectasis usually is the result of an infection or other condition that injures the walls of airways or prevents the airways from clearing mucus. In bronchiectasis, the airways slowly lose their ability to clear out mucus. When mucus cannot be cleared, it builds up and creates an environment in which bacteria can grow. This leads to frequent and serious lung infections.

Access Report Summary with Detailed TOC on "“Bronchiectasis Therapeutics Pipeline Analysis, 2017 - Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments” at:

Various technology platform for bronchiectasis drug development

Insmed’s liposomal technology is designed specifically for the delivery of pharmaceuticals to the lung. Liposomes are the microscopic membrane shells that contain water. In a liposome drug delivery system, water-soluble drugs such as amikacin, are located in the liposome’s water core. The liposome delivery system delivers medicine directly to the site of the lung infection. The infecting bacteria invade and multiply mainly within macrophages. The materials found in a patient’s mucus and biofilms that are produced by bacteria to protect themselves have negative charges which attracts opposite charged antibiotics such as amikacin.

Synthetic sources being used for the development of drugs

The research also found that there are several companies that use synthetic sources for the development of drugs for the treatment of bronchiectasis.

Some of the other key players developing drugs for the treatment of bronchiectasis include Aradigm Corporation, Bayer AG, Zambon SpA and others.

Bronchiectasis Pipeline Analysis

  • By Phase
  • By Molecule Type
  • By Route of Administration
  • By Company